Sei Investments Co. Purchases 7,067 Shares of Abivax SA Sponsored ADR $ABVX

Sei Investments Co. increased its position in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) by 8.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 94,220 shares of the company’s stock after acquiring an additional 7,067 shares during the quarter. Sei Investments Co.’s holdings in Abivax were worth $10,494,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. TCG Crossover Management LLC increased its position in Abivax by 17.4% in the third quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock worth $603,774,000 after purchasing an additional 1,055,000 shares during the period. UBS Group AG lifted its position in Abivax by 2,561.0% during the 3rd quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock valued at $378,761,000 after purchasing an additional 4,293,606 shares during the period. Darwin Global Management Ltd. lifted its position in Abivax by 0.4% during the 4th quarter. Darwin Global Management Ltd. now owns 3,178,501 shares of the company’s stock valued at $439,714,000 after purchasing an additional 14,000 shares during the period. Morgan Stanley lifted its position in Abivax by 114.3% during the 4th quarter. Morgan Stanley now owns 3,151,994 shares of the company’s stock valued at $425,062,000 after purchasing an additional 1,681,277 shares during the period. Finally, Vestal Point Capital LP boosted its stake in shares of Abivax by 90.0% in the 4th quarter. Vestal Point Capital LP now owns 1,900,000 shares of the company’s stock valued at $256,224,000 after purchasing an additional 900,000 shares during the last quarter. Institutional investors own 47.91% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ABVX. Leerink Partners lifted their price target on shares of Abivax from $140.00 to $148.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 30th. Piper Sandler lifted their target price on shares of Abivax from $165.00 to $175.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. Citizens Jmp reiterated a “market outperform” rating and set a $187.00 target price on shares of Abivax in a research report on Wednesday, July 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Abivax in a research report on Friday, July 17th. Finally, Wedbush upped their price objective on Abivax from $90.00 to $110.00 and gave the company a “neutral” rating in a report on Tuesday, June 30th. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $156.50.

Abivax Price Performance

NASDAQ ABVX opened at $124.92 on Friday. Abivax SA Sponsored ADR has a one year low of $67.09 and a one year high of $148.83. The firm has a market cap of $10.90 billion, a P/E ratio of -23.98 and a beta of 0.87. The stock’s 50-day moving average is $118.54 and its 200-day moving average is $118.41.

Abivax (NASDAQ:ABVX) last issued its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.94) by $0.23. The business had revenue of $1.56 million during the quarter, compared to analyst estimates of $0.40 million. Equities analysts anticipate that Abivax SA Sponsored ADR will post -3.22 EPS for the current year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.